The Performance of Prostate Specific Antigen for Predicting Prostate Cancer is Maintained After a Prior Negative Prostate Biopsy

Journal of Urology

Volumn 180, Issue 2, 2008, Pages 544-547

  Thompson, Ian M ^a   Tangen, Catherine M ^c   Ankerst, Donna P ^a   Chi, Chen ^c   Lucia, M Scott ^d   Goodman, Phyllis ^c   Parnes, Howard ^e   Coltman Jr , Charles A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Southwest Oncology Group   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

mass screening; prostate specific antigen; prostatic neoplasms; sensitivity and specificity

Indexed keywords

PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CONFIDENCE INTERVALS; DIGITAL RECTAL EXAMINATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROC CURVE; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 46449127037     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.04.014     Document Type: Article

References (14)

1. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276
2. Sirovich B.E., Schwartz L.M., and Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA 289 (2003) 1414
3. Carter H.B. Prostate cancers in men with low PSA levels-must we find them?. N Engl J Med 350 (2004) 2292
4. Nadler R.B., Loeb S., Roehl K.A., Antenor J.A., Eggener S., and Catalona W.J. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 174 (2005) 2154
5. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
6. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
7. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089
8. Lee R., Localio A.R., Armstrong K., Malkowicz S.B., Schwartz J.S., and Free PSA Study Group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67 (2006) 762
9. Martin B.J., Cheli C.D., Sterling K., Ward M., Pollard S., Lifsey D., et al. Prostate specific antigen isoforms and human glandular kallikrein 2-which offers the best screening performance in a predominantly black population?. J Urol 175 (2006) 104
10. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M.J., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532
11. Punglia R.S., D'Amico A.V., Catalona W.J., Roehl K.A., and Kuntz K.M. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335
12. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
13. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66
14. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297